UroGen Pharma Ltd. Operating Lease, Impairment Loss
UroGen Pharma Ltd. (URGN) reported Operating Lease, Impairment Loss of $0 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseImpairmentLoss · last filed 2026-05-06
- UroGen Pharma Ltd. operating lease, impairment loss for the quarter ending 2026-03-31 was $0.00.
- UroGen Pharma Ltd. operating lease, impairment loss for the quarter ending 2025-12-31 was $0.00.
- UroGen Pharma Ltd. operating lease, impairment loss for the quarter ending 2025-09-30 was $0.00.
- UroGen Pharma Ltd. operating lease, impairment loss for the quarter ending 2025-06-30 was $0.00.
- UroGen Pharma Ltd. operating lease, impairment loss for fiscal 2025 was $0.00.
- UroGen Pharma Ltd. operating lease, impairment loss for fiscal 2024 was $0.00.
- UroGen Pharma Ltd. operating lease, impairment loss for fiscal 2023 was $0.00.
- UroGen Pharma Ltd. operating lease, impairment loss for fiscal 2022 was $0.00.
| Period end | Operating Lease, Impairment Loss 1 month | Operating Lease, Impairment Loss 3 month | Operating Lease, Impairment Loss 6 month | Operating Lease, Impairment Loss 9 month | Operating Lease, Impairment Loss 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $0.00 derived: sum of 3 quarters · filed 2026-05-06 | $0.00 derived: sum of 4 quarters · filed 2026-05-06 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2025-11-06 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2025-08-07 | $0.00 derived: sum of 4 quarters · filed 2025-08-07 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-12 | $0.00 derived: sum of 2 quarters · filed 2025-05-12 | $0.00 derived: sum of 3 quarters · filed 2025-05-12 | $0.00 derived: sum of 4 quarters · filed 2025-05-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2025-03-10 | $0.00 derived: sum of 2 quarters · filed 2025-03-10 | $0.00 derived: sum of 3 quarters · filed 2025-03-10 | $0.00 10-K · filed 2025-03-10 | |
| 2024-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 3 quarters · filed 2024-11-06 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 | $0.00 derived: sum of 2 quarters · filed 2024-08-13 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-13 | ||||
| 2023-12-31 | $0.00 10-K · filed 2024-03-14 | ||||
| 2022-12-31 | $0.00 10-K · filed 2023-03-24 | ||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | |||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-13 | ||||
| 2020-10-31 | $200.00K 10-Q · filed 2022-08-11 | ||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 4 quarters · filed 2020-11-09 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | $0.00 derived: sum of 3 quarters · filed 2020-08-10 | $0.00 derived: sum of 4 quarters · filed 2020-08-10 | |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2020-05-07 | $0.00 derived: sum of 3 quarters · filed 2020-05-07 | $0.00 derived: sum of 4 quarters · filed 2020-05-07 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $0.00 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |